This article explores the rising trend of microdosing semaglutide, a diabetes drug, for its purported non-weight loss benefits like reduced inflammation, improved mental clarity, and reduced risk of neurodegenerative diseases. The article highlights anecdotal evidence from individuals and medical professionals, discussing the drug's potential impact on various health conditions.
On a chilly January evening, Samira Shamoon, a 44-year-old health and beauty publicist, walked into an Italian restaurant to meet friends. They were stunned by the incandescence of her skin. Her cheekbones appeared more defined. After a flurry of questions about which dermatologist or plastic surgeon she had visited, she said, beaming, “I’m microdosing!”
Microdosing can have a lasting effect in achieving a mental edge, says Dr. Anetta Reszko, a Park Avenue dermatologist. “Unlike traditional dosing, which primarily targets appetite suppression and glucose regulation, microdosing semaglutide may provide a more gradual, sustained effect on the brain, immune system and overall cellular health,” she notes. “By modulating these pathways, it may help reduce neuroinflammation, a key factor in cognitive decline and neurodegenerative diseases.
The patients of Los Angeles internist and obesity specialist Pooja Gidwani are microdosing GLP-1s as part of a longevity approach. “It’s becoming more and more mainstream in the Hollywood community, and many want to do this in combination with peptides,” says Gidwani, who offers GLP-1s along with IVs of the co-enzyme NAD.
MICRODOSING SEMAGLUTIDE GLP-1 INFLAMMATION MENTAL CLARITY
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Combining Calorie Restriction and Diabetes Drug Reverses Type 2 Diabetes in Nearly Half of PatientsA new clinical trial shows that combining a moderate calorie-restricted diet with the diabetes drug dapagliflozin achieved type 2 diabetes remission in nearly 44% of participants.
Read more »
The Miracle Molecule and the Morality of Weight LossThis article explores the history of insulin and the rise of semaglutide, a drug that has revolutionized diabetes treatment and weight loss. It highlights the story of Erik Hageman, a man who survived childhood diabetes thanks to Hans Christian Hagedorn's pioneering work with insulin. The article also examines the ethical challenges facing Novo Nordisk, the company that produces both insulin and semaglutide, as it navigates the complex interplay of profit, patient care, and global health.
Read more »
Diabetes Drug Protects Against Skin Cancer, New Research SaysA popular diabetes drug can provide protection against skin cancers, a new study says.
Read more »
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall shortZepbound and Mounjaro have now underperformed expectations for two straight quarters.
Read more »
Eli Lilly Posts Solid Q4 Earnings Fueled by Diabetes and Obesity Drug SalesEli Lilly and Co. reported strong fourth-quarter earnings, driven by the success of its diabetes and obesity medications, Mounjaro and Zepbound. While sales fell short of some analysts' expectations, the company's overall performance exceeded forecasts, with revenue surging 45% and profits reaching $4.41 billion.
Read more »
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025Affiliate. Compare 10 weight loss medications to find the right one for you.
Read more »